Carlotta Defferrari

467 total citations
23 papers, 235 citations indexed

About

Carlotta Defferrari is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Carlotta Defferrari has authored 23 papers receiving a total of 235 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Carlotta Defferrari's work include Lung Cancer Treatments and Mutations (13 papers), Colorectal Cancer Treatments and Studies (8 papers) and Lung Cancer Research Studies (7 papers). Carlotta Defferrari is often cited by papers focused on Lung Cancer Treatments and Mutations (13 papers), Colorectal Cancer Treatments and Studies (8 papers) and Lung Cancer Research Studies (7 papers). Carlotta Defferrari collaborates with scholars based in Italy, United Kingdom and United States. Carlotta Defferrari's co-authors include Francesco Grossi, Marianna Aita, Alessandro Follador, Ornella Belvedere, P. Pronzato, Gianpiero Fasola, Giovanni Pappagallo, Orazio Vinante, Francesco Rosetti and Andrea DeCensi and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

Carlotta Defferrari

21 papers receiving 232 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Carlotta Defferrari Italy	8	150	136	71	38	24	23	235
Johan Pluvy France	6	113 0.8×	129 0.9×	33 0.5×	44 1.2×	13 0.5×	14	171
Manuela Machado Portugal	7	126 0.8×	194 1.4×	47 0.7×	39 1.0×	74 3.1×	19	267
Wei‐Sen Lam Australia	7	143 1.0×	107 0.8×	27 0.4×	6 0.2×	13 0.5×	15	230
Qing Chang China	7	179 1.2×	239 1.8×	55 0.8×	32 0.8×	29 1.2×	21	308
Soon-Chan Hong South Korea	11	198 1.3×	54 0.4×	99 1.4×	47 1.2×	140 5.8×	30	381
Mei Xie China	11	99 0.7×	100 0.7×	93 1.3×	65 1.7×	27 1.1×	28	251
Kevin Rhee United States	5	75 0.5×	38 0.3×	68 1.0×	36 0.9×	28 1.2×	7	153
Gianluca Businello Italy	10	86 0.6×	116 0.9×	60 0.8×	50 1.3×	81 3.4×	22	264
Rüveyda Ayasun United States	6	66 0.4×	57 0.4×	47 0.7×	24 0.6×	30 1.3×	10	165
Sreelakshmi Mallappa United Kingdom	6	32 0.2×	146 1.1×	56 0.8×	50 1.3×	69 2.9×	14	219

Countries citing papers authored by Carlotta Defferrari

Since Specialization

Citations

This map shows the geographic impact of Carlotta Defferrari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carlotta Defferrari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carlotta Defferrari more than expected).

Fields of papers citing papers by Carlotta Defferrari

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carlotta Defferrari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carlotta Defferrari. The network helps show where Carlotta Defferrari may publish in the future.

Co-authorship network of co-authors of Carlotta Defferrari

This figure shows the co-authorship network connecting the top 25 collaborators of Carlotta Defferrari. A scholar is included among the top collaborators of Carlotta Defferrari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carlotta Defferrari. Carlotta Defferrari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Defferrari, Carlotta, et al.. (2025). Rate of growth of Merkel cell carcinoma: a unique photographic evidence. Dermatology Reports.

Webber, Tania Buttiron, Matteo Puntoni, Matteo Clavarezza, et al.. (2021). Patient‐ versus physician‐reported outcomes in a low‐dose tamoxifen trial in noninvasive breast cancer. The Breast Journal. 27(11). 817–823. 5 indexed citations

Webber, Tania Buttiron, Nicoletta Provinciali, Carlotta Defferrari, et al.. (2021). Home Se-Cure: A Home Care Service for Cancer Patients during the COVID-19 Pandemic. International Journal of Environmental Research and Public Health. 18(20). 10913–10913. 1 indexed citations

Passiglia, Francesco, Enrica Capelletto, Francesco Grossi, et al.. (2019). The elderly patient individualized chemotherapy (EPIC) trial, a study for an aged population of non-small cell lung cancer. Annals of Oncology. 30. v656–v656. 2 indexed citations

Maric, Irena, Mariangela Rutigliani, Francesco Lanza, et al.. (2018). Prognostic value of chromosomal imbalances, gene mutations, and BAP1 expression in uveal melanoma. Genes Chromosomes and Cancer. 57(8). 387–400. 20 indexed citations

Puntoni, Matteo, Marco Piccininno, Arnoldo Piccardo, et al.. (2016). Association of Biomarkers with Serious Cardiac Adverse Events during Abiraterone Acetate Treatment in Castration Resistant Prostate Cancer. Translational Oncology. 9(6). 600–605. 9 indexed citations

Puntoni, Matteo, Marilena Petrera, Elsa Garrone, et al.. (2016). Prognostic Significance of VEGF after Twenty-Year Follow-up in a Randomized Trial of Fenretinide in Non–Muscle-Invasive Bladder Cancer. Cancer Prevention Research. 9(6). 437–444. 20 indexed citations

D’Amico, Mauro, Matteo Puntoni, Matteo Clavarezza, et al.. (2014). An observational study of nasal cavity toxicity in cancer patients treated with bevacizumab. Expert Opinion on Drug Safety. 13(11). 1437–1442. 7 indexed citations

Defferrari, Carlotta, Mauro D’Amico, Arnoldo Piccardo, et al.. (2012). A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer. Journal of Ovarian Research. 5(1). 17–17. 3 indexed citations

10.

Grossi, Francesco, Erika Rijavec, Maria Giovanna Dal Bello, et al.. (2012). The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib. Cancer Chemotherapy and Pharmacology. 69(6). 1407–1412. 9 indexed citations

11.

Belvedere, Ornella, Alessandro Follador, C. Rossetto, et al.. (2011). A randomised phase II study of docetaxel/oxaliplatin and docetaxel in patients with previously treated non-small cell lung cancer: An Alpe–Adria Thoracic Oncology Multidisciplinary group trial (ATOM 019). European Journal of Cancer. 47(11). 1653–1659. 4 indexed citations

12.

Grossi, Francesco, Marianna Aita, Carlotta Defferrari, et al.. (2009). Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach. The Oncologist. 14(5). 497–510. 49 indexed citations

13.

Aita, Marianna, Gianpiero Fasola, Carlotta Defferrari, et al.. (2008). Targeting the VEGF pathway: Antiangiogenic strategies in the treatment of non-small cell lung cancer. Critical Reviews in Oncology/Hematology. 68(3). 183–196. 27 indexed citations

14.

Grossi, Francesco, et al.. (2008). Chemotherapy plus bevacizumab in the first-line treatment of non-small cell lung cancer: benefits, risks and limitations. memo - Magazine of European Medical Oncology. 1(1). 13–16.

15.

Grossi, Francesco, Carlotta Defferrari, Orazio Vinante, et al.. (2007). B2-07: Impact of 3rd generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer (NSCLC): a meta-analytical approach. Journal of Thoracic Oncology. 2(8). S339–S339. 2 indexed citations

16.

Grossi, Francesco, Carlotta Defferrari, Maura Loprevite, et al.. (2007). P3-089: Gefitinib (G) treatment outcome after progression on erlotinib (E) in patients with advanced non-small-cell lung cancer (NSCLC). Journal of Thoracic Oncology. 2(8). S716–S717. 1 indexed citations

17.

Grossi, Francesco, Carlotta Defferrari, Maria Giovanna Dal Bello, et al.. (2007). 6625 POSTER Gefitinib (G) treatment outcome after progression on erlotinib (E) in patients with advanced non-small-cell lung cancer (NSCLC). European Journal of Cancer Supplements. 5(4). 395–395. 1 indexed citations

18.

Grossi, Francesco, et al.. (2007). Sequential, Alternating, and Maintenance/Consolidation Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Review of the Literature. The Oncologist. 12(4). 451–464. 57 indexed citations

19.

Grossi, Francesco, et al.. (2007). Gefitinib (G) treatment outcome after progression on erlotinib (E) in patients with advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 25(18_suppl). 18138–18138. 2 indexed citations

20.

Rinaldi, Monica, et al.. (2006). Maintenance chemotherapy in non-small cell lung cancer. Annals of Oncology. 17. ii67–ii70. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact